Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Novavax, Inc.

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Novavax, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

From 2014 to 2023, Novavax's R&D expenses surged by over 900%, peaking in 2021 with a remarkable $2.5 billion investment. This spike coincides with the global demand for vaccines, highlighting Novavax's pivotal role in addressing public health challenges. Meanwhile, Sarepta Therapeutics consistently increased its R&D spending, with a notable 830% rise over the same period, reaching nearly $877 million in 2023. This steady growth underscores Sarepta's focus on developing groundbreaking therapies for rare diseases.

These trends not only showcase the companies' strategic priorities but also emphasize the broader industry's reliance on robust R&D to drive future breakthroughs.